

	Association of Pharmaceutical Research and Development				Appe	ndix 3 - template								
													ication: 16/06/202 osure Report - Fina	
	Full name	Full name Principal Practice Principal Practice Principal Practice Of Principal Practice					Fees for service and consultancy (Ar. 14.3.2 i 14.3.3)							
	(Ar. 14.1.1)	(Ar. 14.3)		(Ar. 14.3)	(Ar 14.3)	Donations and Grants to HCOs (Ar. 14.3.3)	Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		TOTAL OPTIONAL	
SH	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
Ĭ														
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
	Aggregate amount attributable to transfers of value to such Recipients - Ar.14.3.4							352 444.87	0.00	1 349 584.52	15 742.40			
	Number of Recipients in aggregate disclosure - Ar.14.3.4							38	0	96	8			
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Ar.14.3.4							100%	0%	100%	100%	1		
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
so														
皇		•		OTHER, NOT INCLUDE	ED ABOVE - where in	formation cannot be disc	losed on an individual ba	sis for legal reasons		•				
	Aggregate amount attributable to transfers of value to such Recipients - Ar.14.3.4					377 600.00	2 622 889.21	0.00	0.00	0.00	0.00			
	Number of Recipients in aggregate disclosure Ar.14.3.4					1	28	0	0	0	0			
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Ar.14.3.4					100%	100%	0%	0%	0%	0%			
8 D	AGGREGATE DISCLOSURE Transfers of Value re Research & Development as defined - Article 14.3.6													
Ľ	<u> </u>	13 February 2015		I ransters of Value re R	esearch & Developn	nent as detined - Articl	9 14.3.6						65 589 284.01	